Monday
Demant, Sonova gain ground at Veterans Affairs in June – GN and Sivantos lag behind
Bavarian Nordic upgrades again following new batch of monkeypox contracts
Vertex doubles down on diabetes – acquires firm and resumes stem cell study
Tuesday
Abbvie to submit Genmab-developed cancer drug for EMA approval
Novartis beats sales expectations for Genmab-developed Kesimpta
Bavarian Nordic gets new order for 1.5 million monkeypox vaccine doses
Leo Pharma on leaving 22 markets: Freeing up resources enables us to invest in unmet drug needs
Boehringer Ingelheim makes million-euro investment in fight against antibiotic resistance
Johnson & Johnson’s Darzalex Q2 sales surpass projections
Wednesday
Biomarin’s hemophilia gene therapy nears European market after US setback
Thursday
Roche reports continued strong demand across portfolio in H1 2022
Roche to reshuffle management and board
Nestlé Health Science partners with Enterome to treat food allergies and bowel inflammation
Friday
CHMP officially recommends Bavarian Nordic’s vaccine for monkeypox in Europe
Amazon to acquire One Medical in USD 3.5bn deal
Audientes to launch new product in Q4
LEGO owner invests USD 40m in skin treatments from fish skin
Bavarian Nordic expects imminent European monkeypox green light
More from MedWatch
USA prepares to drop public health emergency status for mpox
The US Health Authorities are ready to declare the public emergency over as cases of mpox, formerly known as monkeypox, plummet.
Ambu, Coloplast and GN helped by relaxation of China's covid policy
The three firms, which all have production facilities in the country, appear to be benefitting from the relaxation of China’s zero-tolerance Covid-19 policy.
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Head of Engineering 
Research Scientist (maternity cover) 
Medical Manager Denmark & Norway 
QA Specialist 
Head Of Business Unit Pharma, Öresund Region, AFRY 
Principal Systems Engineer 
Chief consultant for Dansk Erhvervs Health and life science 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Supply Chain Manager 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Laboratory assistants for an exciting QC department